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Abstract 
Cardiac remodeling and failure are regulated by a myriad of cardiac protein phosphorylations. In the present study, 
cardiac phosphoprotein patterns were examined in rodent and human hearts Left ventricular tissue samples were 
obtained from human systolic failing (n = 5) and control (n = 5) hearts and from two rat models of hypertensive 
heart failure, i.e., spontaneously hypertensive heart failure and Dahl salt-sensitive rats and corresponding controls. 
Phosphoproteins were separated by 2D-DIGE with Cydye staining, phosphoprotein patterns were analyzed using 
pixel intensity in rectified images. Specific phosphoproteins which were different in human versus rodent hearts were 
identified by MALDI-TOF/TOF Mass Spectrometry. Targeted pair-wise analyses showed differences (p < 0.05) in 26 % of 
the pixels, which included pixels containing phosphorylated troponin T, myosin light chain, peroxiredoxin, and hapto-
globin. These results show differences in rodent versus human cardiac remodeling which will influence the translation 
rodent studies to humans in this area.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Rodents have become a mainstay for many studies of 
molecular mechanisms and signaling in cardiac fail-
ure. Hypertensive rats undergo a similar morphologic 
progression in cardiac remodeling, including a phase of 
concentric hypertrophy followed by dilation and systolic 
failure, as observed in human hypertension.
Current evidence is overwhelming that protein phos-
phorylations play a key role in regulating cardiac func-
tion/remodeling and contractility in heart failure. First, 
a number of serine-threonine protein kinases and kinase 
signaling pathways have been shown to be capable of 
regulating features of cardiac remodeling. Among these 
are Phosphoinositide 3-Kinase (Cantley 2002; Shioi et al. 
2000), Akt (Shiojima and Walsh 2006; Schiekofer et  al. 
2006; Wohlschlaeger et  al. 2007). GSK-3 (Shioi et  al. 
2000; Matsui et al. 2002; Blankesteijn et al. 2008), trans-
forming growth factor- (Wrana et  al. 1994; Liu et  al. 
2006), Ca(2+)-calmodulin-dependent protein kinase 
(Zhu et al. 2003; Zhang et al. 2002, 2005), cAMP-depend-
ent protein kinase (Benkusky et al. 2007; Lai et al. 2008) 
(Takahashi et al. 2006; Fukuda et al. 2005), Protein kinase 
D1 (Fielitz et  al. 2005; Harrison et  al. 2006), Mitogen-
activated protein kinases (Frantz et  al. 2007), and Pro-
tein kinase C (Agnetti et al. 2007; Sumandea et al. 2004; 
Sumandea et  al. 2003). Second, protein phosphatases, 
e.g., phosphatases 1 (PP1 and PP2) (Grote-Wessels et al. 
2008) (Gupta et  al. 2003, 2005) (Grote-Wessels et  al. 
2008; Pathak et al. 2005) and Calcineurin (Dousa 1999). 
(Van Oort et al. 2006) (Sakata et al. 2000; Heineke et al. 
2005), regulate cardiac remodeling in heart failure. Third, 
a number of phosphoproteins identified that may be 
proximal mediators of cardiac remodeling are increasing: 
These include Phospholamban (PLN), (Napolitano et al. 
1992; Movsesian et al. 1990; Vittone et al. 2008; Altschuld 
et al. 1995; Schwinger et al. 1998; Desantiago et al. 2008); 
Connexin 43 (Akar et  al. 2004; Ai and Pogwizd 2005), 
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Endothelial nitric oxide synthase (eNOS) (Gill et  al. 
2005), histone deacetylase (HDAC) (Zhang et  al. 2002), 
Protein kinase C (Vega et al. 2004), a variety of myofila-
ment proteins (Belin et  al. 2007), including troponin I 
(Milting et al. 2006); myosin light chain (Papp et al. 2003), 
and the cAMP response element binding protein (Takei-
shi et al. 2002; Muller et al. 1995, 1998, 2001; Matus et al. 
2007); the Ryanidine Receptor (RyR) (Lehnart et al. 2005) 
and O transcription factor (Skurk et  al. 2005; Vahtola 
et al. 2008). Delineation of cellular phosphoprotein sign-
aling pathways is the result of numerous distinct stud-
ies using a wide variety experimental models, including 
in  vitro studies with cell culture, isolated proteins, iso-
lated cardiac myocytes, in vitro work with cardiac prep-
arations and whole animals from numerous species and 
strains over the past 70 years.
In the present study, we have examined and compared 
phosphoprotein patterns in humans versus rodent hearts. 
The important question we asked in the present study is 
translational feasibility and efficacy of findings of rodent 
heart failure studies to human subjects.
The aims of the study were to compare phosphoprotein 




Left ventricular tissue from non-failing and failing 
human hearts. Samples of left ventricular (LV) tissue 
were obtained from Loyola University Health System’s 
(LUHS’s) Cardiovascular Institute Tissue Repository, and 
from the Gift of Hope Organ and Tissue Donor Network. 
The investigation conformed to the principles outlined 
in the Declaration of Helsinki. A detailed protocol and 
informed consent document were reviewed by LUHS’s 
Institutional Review Board prior to tissue procurement. 
Following informed consent, explanted LV tissue was 
obtained from patients undergoing heart transplantation 
for nonischemic, dilated cardiomyopathy (DCM). Tissue 
samples were quick-frozen in liquid N2 in the operating 
room and stored at −80  °C. Following informed con-
sent from organ donor family members, nonfailing (NF) 
donor hearts judged unsuitable for cardiac transplanta-
tion were stored in cardioplegic solution on ice and were 
delivered within 4  h of cardiac extirpation by the Gift 
of Hope Organ and tissue Donor Network. Tissue sam-
ples were then quickly frozen in liquid N2, and stored at 
−80 °C.
Rodent hearts
2D-DIGE images of phosphoprotein were extracted 
from paired strains of failing and control rats strains, i.e., 
(1) Dahl salt-sensitive (S) (failing) versus resistant (R) 
(control) rat; and (2) Spontaneously hypertensive stroke 
prone (SHHF) (failing) and Wistar (control) rat strains 
and as previously reported and described (Kotlo et  al. 
2012).
Protein preparation with phospho‑enrichment
Total protein extracts were obtained by dounce homog-
enizing (left ventricular tissue) and resuspending pelleted 
regenerated cardiomyocytes in RIPA buffer containing 
a protease inhibitor cocktail mixture (Calbiochem) with 
phosphatase inhibitors (50  mM sodium fluoride, 1  mM 
sodium orthovanadate and 1  mM sodium pyrophos-
phate). The homogenate was centrifuged at 14,000  rpm 
for 15  min at 4  °C, and the supernatant subjected to 
phosphoenrichment of proteins using a Phosphoprotein 
purification kit supplied by Qiagen Inc according to the 
manufacturer’s instructions.
2-D DIGE with Cydye staining was performed for in-
gel comparison of cardiac phosphoproteins. Phospho-
enriched proteins were dissolved in 2-D lysis buffer (7 M 
urea, 2  M thiourea, 4  % CHAPS, 30  mM Tris-HCl, pH 
8.8). Protein concentration was determined using the Bio-
Rad protein assay method and samples diluted with 2-D 
lysis buffer to protein concentration between 5 and 8 mg/
ml. 1.0 µL of diluted CyDye (1:5 diluted with DMF from 
1  nmol/µL stock) is added to 30  µg of protein extract. 
Cy2 was used for control samples and Cy5 was used for 
heart failure samples. The mixture was vortexed and 
then incubated under dark conditions on ice for 30 min. 
1.0  µL of 10  mM Lysine was added to each of the sam-
ples to quench the reaction, followed by vortexing and 
incubation under dark conditions on ice for an addi-
tional 15 min. Cy2 and Cy5 labeled samples were mixed 
together and the appropriate volume of 2X  2-D Sample 
Buffer (8 M urea, 4 % CHAPS, 20 mg/ml DTT, 2 % phar-
malytes, and trace amounts of bromophenol blue) and 
100  µL of destreak solution (GE Healthcare) was added 
to the samples. Rehydration buffer (7 M urea, 2 M thio-
urea, 4 % CHAPS, 20 mg/ml DTT, 1 % pharmalytes, and 
trace amounts of bromophenol blue) was added to reach 
a total volume of 250 µL. The samples were mixed, spun, 
and equal amounts of protein were loaded onto 13  cm 
IPG strips (pH 3–10 linear) under 1 ml mineral oil. Iso-
electric focusing was performed for 12 h at 20°C with 50 
µA/strip. The focused IPG strips are loaded into the 12 % 
SDS-gels and ran at 15  °C until the dye front ran out of 
the gels. Image scans are carried out immediately follow-
ing the SDS-PAGE using Typhoon TRIO (Amersham Bio-
Sciences) according to the manufacturer’s instructions.
Image registration
Scanned 2D-DIGE images were analyzed by Image 
QuantTL software (GE-Healthcare). The scanned gel 
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images were saved as grayscale Tagged Image File For-
mat (TIFF) files. Each pixel in these files had an intensity 
value that ranged from integers 0 to 255. Rectification 
points were determined by visual examination of each 
of the gels. Each image file was annotated with the loca-
tion of 19 common points that were used for image reg-
istration (Fig. 1). All the images were transformed using 
spline interpolation functions available in ESRI ArcMap 
10.1 software. This transformation ensures that the loca-
tions of the 19 control points are preserved exactly and 
the locations of pixels between the control points are 
transformed using a smooth function (Brown 1992). The 
resulting images were resampled and cropped to a box 
that bounds the control points. The resulting images con-
tained 509 rows and 489 columns for a total of 248,901 
pixels.
MALDI‑TOF/TOF mass spectrometry
Protein spots were excised by Ettan Spot Picker (GE 
Healthcare) and washed multiple times to remove stain-
ing Cy dyes and other inhibitory chemicals. Gel spots 
were dried and then rehydrated in digestion buffer 
containing sequencing grade modified trypsin. Proteins 
were digested in-gel at 37  °C and digested peptides are 
extracted from the gel with TFA extraction buffer and 
shaking. The digested tryptic peptides were desalted using 
C-18 Zip-tips (Millipore) and then mixed with CHCA 
matrix (alpha-cyano-4-hydroxycinnamic acid) and spot-
ted into the wells of a MALDI plate. Mass spectra (MS) 
of the peptides in each sample were obtained using an 
ABSciex 4700 Proteomics Analyzer and ten to twenty of 
the most abundant peptides in each sample were further 
subjected to fragmentation and tandem mass spectrom-
etry (MS/MS) analysis. The combined MS and MS/MS 
spectra were submitted for database search using GPS 
Explorer software equipped with the MASCOT search 
engine to identify proteins from the NCBI non-redundant 
protein database. Proteins identified with a confidence 
interval (C.I.) greater than 99 % are reported.
Statistics
The differences between sets of images were examined on 
a pixel by pixel basis. Spot abundance was determined by 
average pixel value of “ovals” containing spots identified 
Fig. 1 Representative 2D-DIGE image of phosphoproteins from control versus failing human heart. Rectification points are circled (lettered). 
Phospho-enriched protein samples from failing and control hearts were differentially labeled with Cydyes (failing = Cy5 red, control = Cy2 green) 
and subjected to 2D-DIGE. Yellow represents the merged spot densities. Molecular weight markers (kDa) are displayed to the left of each gel and pH 
markers are displayed underneath each gel
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visually. Student’s t test was used to test for a difference 
in mean abundance between normal and failing human 
hearts and between all of the human hearts and the 
rodent hearts. The significance of these comparisons was 
assessed using the false discovery rate (FDR) (Benjamini 
and Hochberg 2014). R version 2.15.1 (The R Project for 
Statistical Computing) was employed to make the com-
parisons and adjust the significance values (R Foundation 
for Statistical Computing 2014). Since some identified 
phosphoproteins were of a priori high interest, these 
were analyzed by t-test (Table 2).
Results
Human hearts
Tissues from failing (n =  5) and control (n =  5) human 
hearts (Table  1) were analyzed. Phosphoproteins from 
each heart were separated by 2D-DIGE (Fig. 1). The dis-
tribution of these favored the right upper and lower quad-
rants, corresponding to proteins with MW’s 80 to 12 kDa/
PI’s 6.8 to 9.0. Registered images were compiled. Mean 
(Fig.  2a) and standard deviation (Fig.  2b) plots showed 
the greatest abundance and variation in the proteins of 
the right upper quadrant. In identifying phosphoproteins 
with the greatest variability (variance in gray-unit scale) 
by 2D-DIGE, there is a bias toward ones with moderate 
abundance, in part due to censoring at extreme low or 
high levels. Ten phosphoproteins were chosen visually on 
the basis of both high abundance and standard deviation 
in composite images (Fig. 2a, b) for identification (Table 2) 
by MALDI-MS. A significant overall difference in 
standard differences in means of control and failing hearts 
(Fig. 3 and Additional file 1) could not be discerned. How-
ever, spot intensity was, in general, lowest in the lower 
right quadrant and greatest in lower left quadrant.   
Rodent hearts
2D-DIGE images of phosphoproteins extracted from 
paired strains of failing and control rats strains, i.e., 1) 
Dahl salt-sensitive (S) and resistant (R) rat; and 2) Spon-
taneously hypertensive heart failure (SHHF) and Wistar 
rat strains (published previously (Kotlo et al. 2012)) were 
analyzed in composite using image registration (Fig.  4). 
The composite rectified images revealed a distribution 
of intensity of spots in all four quadrants, with the great 
concentration and variation in the right upper quadrant 
(Fig. 4).
Comparison of cardiac phosphoproteins in humans 
versus rats
The composite registered images from phosphoproteins 
extracted from human and rat hearts were compared 
(Figs. 5, 6). The range of differences in mean abundance 
for phosphoproteins from control versus failing human 
hearts was −15 to 12.67, versus a range for human vs. 
rat differences of −116 to 227. Mean and variance were 
different in human versus rodent hearts in 26  % of the 
image planes. Mean abundance for the humans was 
lower than for the rodents in focal areas in each of the 
four quadrants and most profound in the left two-thirds 
of the images. The mean pixel intensity was higher for 
Table 1 Human heart samples analyzed by 2D-DIGE and MALDI-TOF
DCM dilated cardiomyopathy, NF non-failing heart (control), EF ejection fraction, NIDDM non-insulin dependent diabetes mellitus, M male, F female
Sample ID Age Gender Race Ejection fraction Cause of death
DCM24 55 M Black 5 % DCM
DCM25 45 M White 5 % DCM
DCM33 23 M Black 15 % DCM
DMC40 33 M White 15 % DCM
DMC41 22 F Black 10 % DCM
NF3 44 M White Echo: none done Cardiac Cath: not done Paranoid Schizophrenia; acute subdural 
hematoma
NF9 50 F Hispanic Echo: Normal LVEF/hyperdynamic/possible mild LVH/No 
obvious vascular lesions, no RWMA, mild pericardial effusion 
Cardiac Cath: normal coronary arteries, no disease or steno-
sis, normal size, normal LV systolic function, EF>70 %
Left basal ganglia hemorrhagic stroke; 
chronic paroxysomal Afib, HTN, 
depression, renal insufficiency, NIDDM
NF16 40 F Black Echo: technically suboptimal study, RV, RA, normal dimensions; 
LA and LV normal dimensions, LV wall motion is normal; no 
gross valvular abnormality; no thrombus, vegetation or effu-
sion; EF estimated @70 % Cardiac Cath: not done
Bipolar Disorder Suicide by methanol 
poisoning; seizures
NF19 61 M White Echo: Not done Cardiac Cath: not done Intracranial hemorrhage
NF20 58 M Black Echo: Global LV systolic function normal, RV systolic functions 
normal, valves normal, no thrombus or effusion; EF~65 % 
Cariac Cath: not done
Intracranial hemorrhage, hypertension, 
DM
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the rat hearts in a large proportion of the right third of 
the images. This analysis shows statistically significant 
(p  <  0.05) differences between cardiac phosphoproteins 
within combined groups of control and failing human 
versus rodent hearts.
The intensity spots for the identified phosphopro-
teins were compared between human and rodent hearts 
(Table  3). Specific phosphoproteins with significant dif-
ferences between human versus rodent hearts were iden-
tified as 60  kDa heat shock protein (spot #13) troponin 
T (spot #18), Myosin Light Chain 3 (spot #25), peroxire-
doxin (spot #27), and haptoglobin (spot #29).
Discussion
In the present study we have applied image registra-
tion to analyze phosphoproteins separated by 2D-DIGE 
from multiple human and rodent control and failing 
hearts in composite. The central findings are that there 
is great biological variability in the abundance of par-
ticular phosphoproteins in human and rodent hearts.
The mean plots constructed from 2D-DIGE images 
show great variation in phosphoproteins in human 
hearts, both within and between normal and failing 
heart samples. There are significant differences in the 
standard deviations and ranges of phosphoprotein abun-
dances, indicating significant inter-individual variation. 
In identifying phosphoproteins with the greatest vari-
ability (variance in gray-unit scale) by 2D-DIGE, there is 
a bias toward ones with moderate abundance, in part due 
to censoring at extreme low or high levels. Variation in 
the present study may not only arise from phosphoryla-
tions but also from variations in other post-translational 
modifications, (e.g., acetylation) which effect either MW 
or PI. However, the rectification and analysis process 
used should minimize this affecting phosphoprotein spot 
measurements.
We reason that the major source of variation in abun-
dance of specific phosphoproteins observed is biological 
variability (versus replicative error). The overall statisti-
cal variation observed in the present study is consist-
ent with that reported for proteomic analysis of human 
plasma (Corzett et al. 2010). 2D-DIGE gel to gel variabil-
ity has previously been reported to be low with three or 
four replicates sufficient for compensation of variability, 
indicating that this does not introduce a significant bias 
with statistical confidence for individual spots (Burton 
and Hickey 2011). The etiology of biological variabil-
ity is reasoned to arise from multiple sources, including 
genetic, environmental, and phenotypic cofounders. 
However, these may be very difficult to control for in that 
the variability of phosphoproteins in both rodents in the 
present and our previous data (Burton and Hickey 2011) 
Fig. 2 Phosphoproteins with greatest density and variability in human hearts. Analyses of composite orthorectified 2D-DIGE images of phos-
phoproteins extracted from human control (n = 5) and systolic failing hearts (n = 5). a Means of phosphoprotein spots. b Standard deviations of 
phosphoprotein spots pixels. Color scales to right of images. Circled spots correspond to identified phosphoproteins by MALDI-TOF (Table 2)
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is marked, suggesting that even when there is greater 
genetic homogeneity and control over environment, 
inherent variability is observed. On the other hand, since 
phosphoproteins have different variability in abundance, 
some may require smaller sample sizes to discern differ-
ence, e.g., cMyBP-C (Kooij et al. 2013).
The variability of specific phosphoproteins in human 
hearts may be used to infer sample sizes required for clini-
cal trials linking a protein modification to a phenotype, e.g., 
heart failure. We can use the biological variability reflected 
in phosphoproteins in the present study to determine requi-
site sample sizes frequently required to link a phosphoryla-
tion to a phenotype using inverse power analyses (Fig.  6). 
These power analysis shows that to detect small differences, 
studies with 1,000 to 10,000 subjects are required, in repre-
sentative phosphoproteins identified in our study. The num-
ber of phosphoproteins with high variability suggests that 
improved phenotyping, which is usually based on a single or 
few indexes, in clinical trials is unlikely to reduce the promi-
nence of inherent biological variability reflected in cell sign-
aling and, required sample size for statistical power.
Rodent models have become a mainstay for the study 
of heart disease and failure, especially with hyperten-
sion. The present results show significant differences 
in the phosphoprotein patterns in rat versus human 
hearts in approximately one quarter of the area of com-
pared rectified 2D-DIGE composite images. Among 
these phosphoproteins are ones known to be important 
in cardiac remodeling and function as well as ones not 
previously linked to the heart. Among the ones linked 
to cardiac functions/adaptation are phosphorylated heat 
shock protein 60 (HSP60) and troponin T. The likeli-
hood of significant differences in phosphorylation of 
Troponin T is consistent with the lack of conservation 
Fig. 3 Composite orthorectified image derived from #10 2D-DIGE images of phosphoproteins extracted from human control (n = 5) and systolic 
failing hearts (n = 5). Color scales to right of images. No standard difference in means of phosphoprotein intensities of human hearts was dis-
cerned (Additional file 1)
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Fig. 4 A composite orthorectified image derived from #4 2D-DIGE images of phosphoproteins extracted from control and failing rat hearts. a 
Means The colors represent the average difference between the controls and failing images and range from light blue (turquois) (small average differ-
ences) through dark blue (significant large average differences) (see color scales). b Standard deviations of means: The colors represent the average 
difference between the controls and failing images and range from light purple (small average differences) through dark purple (123) (see color scale) 
(n = 4). Greatest difference in phosphoprotein density and variability is noticed in the upper right quadrant
Fig. 5 Comparison of phosphoproteins in rodent versus human hearts. a Standardized differences. b Significance map. The bright pink areas indi-
cate protein phosphorylations that are different between control and failing hearts. The light blue (turquois) areas indicate protein phosphorylations 
that are most uniform across all the heart samples. rat > human—red; human > rat—green
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of phosphorylation motifs, e.g., troponin I Thr77 (review 
(Grzeskowiak et  al. 2003)) in rodents versus humans. 
These findings may have major implications in the 
translation of rodent studies of the role of the phospho-
rylations of these proteins to humans and highlight the 
difficulties of such work (Hackam and Redelmeier 2006).
Conclusions
There are significant differences in the phosphorylation 
of key cardiac proteins in rodents and humans, makes 
confirmation of cardiac signaling involving phosphoryla-
tions, e.g., kinases, phosphodiesterases, phosphatases, 
in rodents in humans critical for translational work. The 
Fig. 6 Inverse power plot demonstrating sample size required to achieve 80 % power with 5 % type 1 error for the given group mean difference 
based on mean and standard deviation of phosphorylated peroxiredoxin (Table 3)
Table 3 Comparison of intensity (see Methods) of phosphoprotein spots selected from Fig. 2/Table 2 for increased abun-
dance and/or variation (SD) in human versus rodent hearts
Spot number—Fig. 2, protein-identification—Table 2; Overall mean/SD—mean and standard deviation of intensity of spots from composite rectified 2D-DIGE images 
of phosphoproteins from rodent and human hearts (Fig. 3). t—t value for human versus rodent
Spot Protein Overall mean Overall SD Human mean Human SD Rat mean Rat SD t p value
1 Cerulpolasmin 63.42 36.12 52.62 25 90.42 49.19 (−) 1.46 0.224
3 ER ATPs e 78.88 46.56 67.45 47.78 107.47 31.94 (−) 1.82 0.104
13 60kD Heat Shock Protein 84.1 32.7 93.82 32.83 59.78 17.21 2.52 0.0289
15 Haptagloblin 85.05 27.84 85.85 28.69 83.06 29.69 0.16 0.8784
16 Actin, alpha cardiac muscle 1 120.84 48.81 122.79 36.78 115.99 78.87 0.17 0.8777
18 Troponin T cardiac muscle 158.51 53.09 134.45 36.39 218.68 38.55 (−) 3.75 0.0119
23 Tropomyosin alpha-1 chain 202.96 44.58 192.67 46.69 228.7 28.9 (−) 1.74 0.1144
25 Myos in light chain 3 99.82 94.05 43.03 14.26 241.81 9.55 (−) 30.27 <0.0001
27 Peroxiredoxin-2 26.18 14.6 31.63 13.86 12.56 1.29 4.3 0.0018
29 Haptagloblin 22.23 28.72 29.04 31.74 5.21 3.36 2.34 0.0425
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variability of specific phosphoproteins observed indicates 
large sample sizes, i.e., 1000–10,000, are required to link 
a phenotype to a phosphoprotein.
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